A new market study, titled “Discover Global Smoking Cessation and Nicotine De-Addiction Therapeutics Market Upcoming Trends, Growth Drivers and Challenges” has been featured on WiseGuyReports.
The addiction of tobacco products like nicotine kills every one person prematurely every six seconds, as reported by the WHO. The nicotine causes not only pathophysiological changes in the human body but also affects the lungs and other parts of the body with repeated use. The repeated exposure to nicotine develops neuroadaptation of the receptors, resulting in the tolerance to the effects of nicotine. The smoking cessation and nicotine de-addiction therapeutics is helping nicotine addicts to quit smoking and reduce the number of nicotine consumers.
Smoking cessation and nicotine de-addiction therapeutics help reduce withdrawal symptoms and block the reinforcing effects of nicotine without causing excessive adverse effects. The various therapeutics like gum, patches and inhalers are being introduced among the consumers for increasing smoking cessation rates in the short and long term. There are effective treatments that support smoking cessation and nicotine-de addiction including FDA approved medications. The FDA approved nicotine de-addiction drugs include bupropion and varenicline. The prevalence of smoking and constant nicotine intake among adolescents and the neurobiological impact and other consequences of nicotine exposure is leading to the increased demand for smoking cessation and nicotine de-addiction therapeutics.
The global smoking cessation and nicotine de-addiction therapeutics market report is primarily studied based on the introduction of new products, advancements in the novel technologies, and the rise in demand for the therapeutics. The global market is being driven by the rising awareness among the global population about the smoking health hazards such as the increased risk of cardiac diseases, respiratory disorders and lung cancer. The growing issues of the dependency on nicotine and the health problems caused by it is leading to the growth of the smoking cessation and nicotine de-addiction therapeutics market.
The global market for smoking cessation and nicotine de-addiction therapeutics can be segmented based on the type as Drug Therapy, Nicotine Replacement Therapy (NRT) and Electronic Cigarettes (E-cigarettes). The NRT is the most significant segment owing to the increased accessibility, simplicity in use and its efficiency in reducing the nicotine cravings in smokers. NRT can be further segmented into Prescription and Over the Counter (OTC). The OTC comprises of Nicotine spray, Nicotine gums, Nicotine inhalers, and Nicotine transdermal patches. Whereas, Prescription sub-segment contains Nicotine sublingual tablets and Nicotine lozenges. The Drug therapy section includes Varenicline and Zyban where Varenicline is a non-nicotine based drug that is quite effective in smoking cessation and Zyban is another broadly used drugs. E-cigarettes are projected to be the most lucrative among all the product segments in the global market owing to the popularity backed by the electronic feature.
The North America region is dominating the global smoking cessation and nicotine de-addiction therapeutics market, attributing to the increase in the number of smokers and the simultaneous increase in the awareness among the population on nicotine effects. The growth in the research fundings and the various government initiatives to create awareness against the dire effects of smoking are some of the factors that are helping the market see profitable growth in the coming years. According to the Centres for Disease Control and Prevention (CDC), 2017, 14 of every 100 U.S. adults aged 18+ years smoked cigarette. This estimated to over 34.3 million adults smoking cigarettes and over 16 million Americans living with a smoking-related disease. Asia-Pacific region is expected to be the fastest-growing market during the forecast period till 2026, owing to the region’s rapidly improving healthcare infrastructure and a broad base of the target population.
The Ministry of Health (MOH) in Kuala Lumpur, Malaysia, has seized 35,439 products that contained unlicensed nicotine worth RM6.8m. The operation was carried out in regards to the complaints and information received from the public on the sale of e-cigarettes containing nicotine-based liquids. The sale of nicotine without a valid license is a punishable offence in Malaysia with a fine not exceeding RM3000 or imprisonment or both, upon conviction.
Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)